12619 results for [current-page:query:search]
Refine Your Search
"News" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Chemotherapy Drug Listing" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
Jean Koff
Dr. Jean Koff is an Associate Professor in the Department of Hematology and Medical Oncology and Director of the Lymphoma Program’s Translational Rese…
Understanding Leukemia in Children with Down Syndrome to Develop Better Therapies
This Specialized Center of Research is focused on identifying the contributions of chromosome , which is present in three copies in individuals with D…
Paolo Caimi
Paolo Caimi is a physician and clinical investigator at the Cleveland Clinic, where he is also the Associate Bone Marrow Transplant Director for Cellu…
Paolo Caimi
Paolo Caimi is a physician and clinical investigator at the Cleveland Clinic, where he is also the Associate Bone Marrow Transplant Director for Cellu…
BAFF-ligand CAR T-cells and pre-apheresis B-cell lymphodepletion for relapsed/refractory CLL
Most CLL patients treated with CAR that target the CD19 antigen on the cell do not achieve a complete remission. CLL cells express other molecules on…
Research: Grants
Epigenetic Mechanisms and Targeting in Hematological Malignancy
Blood cancers can be caused by aberrant regulation of genes that control cell growth and development. The root cause of this problem may be the presen…
Genomic and epigenomic interactions of complex structural variants affecting outcome in multiple myeloma
Multiple myeloma is characterized by severe changes in chromosomes that result in gains or losses of genetic material. Several key events disrupt the …
Modeling LSC heterogeneity at unprecedented resolution in AML
Our goal is to perform molecular characterization of human leukemia stem cells (LSCs). We have developed an integrated set of techniques that will a…
Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma
Peripheral lymphomas are highly aggressive blood cancer that have very poor survival rate, highlighting the need for new therapies to improve patient…
Teresa Palomero
Dr. Teresa Palomero is a molecular and cellular biologist. She is a Professor at Columbia University in the Institute for Cancer Genetics. Her laborat…
Interrogating T-cell apoptotic priming to improve CAR-T persistence in treatment of lymphoid malignancies
cells are made from a patient’s own immune cells, altered so that they specifically recognize and kill the patient’s cancer cells. They are effective …
Anthony Letai
Dr. Letai is a Professor of Medicine at Harvard Medical School and Cancer Institute. He began his studies in apoptosis and hematologic malignancies a…
Defining mechanisms of sensitivity and resistance to PI3K gamma inhibition in AML
The goal of our laboratory is to discover, study, and the translate new leukemia therapies to the clinic. In this project, we are studying a signaling…
Next-Generation Targeted Therapy in Mantle Cell Lymphoma and Transformed Follicular Lymphoma
The field of cancer treatment has made remarkable progress with the adoption of targeted therapy; however, small molecule drugs have limitations such …
Steven Park
I am a physician scientist, specializing in lymphoma therapy. My area of research is focused on the development of new therapeutic approaches in lymph…
Supplier resources
Get all the tools you need to work better with Blood Cancer United.
A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with myelofibrosis
In August , TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of SEL120 in Patients With Acute Myeloid Leu…
A phase 2 study of RVU120, a novel CDK8 inhibitor, in patients with low-risk MDS
In August , TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of SEL120 in Patients With Acute Myeloid Leu…
A phase 2 study of RVU120, a novel CDK8 inhibitor, in combination with venetoclax in patients with AML
In August , TAP partnered with Ryvu Therapeutics (formerly known as Selvita) to support "A Phase 1b Study of SEL120 in Patients With Acute Myeloid Leu…
A phase 1 study of DR-0201, a bispecific myeloid engager, in patients with B-NHL
In November , LLS made an equity investment in Dren Bio to "Support Clinical Development of the Program for Rare Leukemia & Lymphoma Indications Incl…
Lower Dose Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
regimens are the standard of care for many patients with acute myeloid leukemia (AML) and are highly active therapeutic strategies for this challengin…
Developing Novel Immunotherapies for Challenging Lymphomas
This team science program from Washington University will develop new immunotherapy treatments for patients with hard to treat or incurable lymphomas.…
Memory-like NK cells after hematopoietic cell transplant to eradicate measurable residual disease
Relapse in patients with acute myeloid leukemia (AML) after hematopoietic cell transplant (HCT) is associated with extremely poor prognosis and thus r…